**Request for Letters of Intent** - Early Career Investigators are Encouraged to Submit

The Erdheim-Chester Disease (ECD) Global Alliance (ECDGA) is soliciting Letters of Intent (LOI) for funding research projects focused on the study of **Erdheim-Chester Disease (ECD) and other Adult Histiocytic Disorders.**

Maximum Amount to be Awarded: Up to **60,000 USD**

Duration of Grant: 2 Years

**LOI Deadline: September 5, 2024**

Eligibility Requirements: Early Career Investigators (international proposals welcomed)

The purpose of the ECD Global Alliance is to help those affected by Erdheim-Chester Disease. As such, the Alliance’s mission is to provide support, promote research, raise awareness, and share educational material related to ECD.

Erdheim-Chester Disease is a rare histiocytic neoplasm. The disorder is characterized by excessive production and accumulation of histiocytes that infiltrate the loose connective tissue of the body. Unless successful treatment is found, organ failure can result. Erdheim-Chester Disease usually affects adults, although childhood cases have been documented. It can affect both men and women. Disease involvement may include any combination of long bones of the legs and arms, skin, tissues behind the eyes, lungs, brain, pituitary gland, kidney, abdominal cavity, heart, adrenal glands, and more rarely other organs.

The ECD Global Alliance is interested in receiving LOIs for any study that has the potential to lead to an increase in knowledge to eventually help address unmet adult histiocytic patient needs, especially those with Erdheim-Chester Disease. All submitted projects must include information explaining how the information to be learned will help ECD patients.

All basic science and clinical research proposals submitted by Early Career Investigators will be considered. **Early career investigators** are individuals who have not received previous funding for the study of ECD and are within ten (10) years of receiving either of the following:

* Terminal research degree or completion of postdoctoral training
* Medical residency, fellowship or equivalent

All qualified and interested Early Investigators are encouraged to submit. As appropriate, submitted studies should consider the inclusion of the following:

* Collaboration among investigators from different institutions
* Translation of findings into the clinical setting
* Use of ECD Registry housed at Memorial Sloan Kettering; PI Eli Diamond, MD (diamone1@mskcc.org)

**Please submit all LOIs in pdf format using attached ‘ECDGA 2024 LOI Submission Form’ to:**

[**https://questionpro.com/t/ATlviZ21av**](https://questionpro.com/t/ATlviZ21av)

**Questions to be sent to:**

[**support@Erdheim-Chester.org**](mailto:support@Erdheim-Chester.org) **+1-337-515-6987 Kathy Brewer**

|  |  |
| --- | --- |
| **SECTION 1: PROJECT OVERVIEW AND CONTACT INFO** | |
| 1. **Title of LOI** | Click or tap here to enter text. |
| 1. **Short title of LOI** *(max 100 characters)* |  |
| 3..**ECDGA Priority**   (Treatment, Diagnosis, Basic Understanding, Natural History, etc.) |  |
| 4a. **Lead Applicant Name** |  |
| 4b. **Lead Applicant Institution** |  |
| 4c. **Lead Applicant Address** |  |
| 1. **Research Team Co-applicants**(include institution names/addresses) |  |
| 6a. **Requested Budget Year 1** |  |
| 6b. **Requested Budget Year 2** |  |
| 1. **Summary of research question and justification in layman's terms**  *(max 1200 characters)* |  |
| 1. **Type of research**  (laboratory/basic science, translational/applied field research, epidemiology, clinical research, health systems research, social science, other) |  |
| 9a. **PI Signature** |  |
| 9b. **Date** |  |
| 9c. **PI email** |  |
| 9d. **PI phone** |  |

|  |  |
| --- | --- |
| **SECTION 2: RESEARCH PROPOSAL** | |
| **1.    Background.** (This section should provide the study rationale, supporting data, and address the following: what is the goal of the study, why is this study important, any potential safety concerns, and how the study results might impact future treatments or research. The background information should be limited to what is relevant to the proposed study and should be presented succinctly but with sufficient detail to enable evaluation by the reviewers.) *(max 2500 characters)* |  |
| **2.    Scientific justification/rationale for the study**  *(max 1500 characters)* |  |
| **3.    Main research question and primary/secondary objective(s)** *(max 925 characters)* |  |
| **4.    Study design** [A one-page schema or flow diagram may be attached, if appropriate.] *(max 1200 characters)* |  |
| **5.    Outcome measure(s) and data collection**  *(max 1200 characters)* |  |
| **6.    Sample size**  *(max 600 characters)* |  |
| **7.    Study population/participant characteristics and sampling (recruitment) strategy**  *(max 1500 characters)* |  |
| **8.    References** (Provide verified references for cited data and key background/concepts.) |  |
| 1. **Research sites** |  |
| **10.  Involvement of ECD-affected patients and/or caregivers** (in the planning, design, and/or management of the study, data collection, analysis, etc.) *(max 925 characters)* |  |
| **11. Management arrangements** (how will the project be managed to ensure it is completed on time and within budget, with full participation of all participants) |  |

|  |
| --- |
| **SECTION 3: TABLE 1: Schedule (Gantt Chart preferred and can be attached.)** |
|  |

|  |
| --- |
| **SECTION 4: TABLE 2: Budget (include year of expected use)** |
|  |

|  |
| --- |
| **SECTION 4: Figure 1 – Optional**  **(If a figure will help explain the proposal, please include a single page figure here.)** |
|  |

**Submissions must be made before midnight (CT) on September 5, 2024.**

Please submit a pdf copy of the completed form, including a biosketch for the PI and each of the collaborators at [**https://questionpro.com/t/ATlviZ21av**](https://questionpro.com/t/ATlviZ21av) **.**

Questions? Please contact Kathleen Brewer at [support@erdheim-chester.org](mailto:support@erdheim-chester.org).